Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Professor Kohei Shitara: Advancing Immunotherapy in Gastrointestinal Cancers—Cancer Vaccines, T-Cell Engagers, and Other Emerging Strategies May Lead the Next Wave 

     Immunotherapy has fundamentally reshaped the treatment landscape of gastrointestinal (GI) cancers. However, now that PD-1/PD-L1 inhibitors have been firmly established as standards of care, the key challenge facing clinical research is how to further overcome the current efficacy plateau. This has driven research into a “deep-water zone,” where novel strategies—such as next-generation TIGIT inhibitors, cancer…

    2025.12.18
  • On-site from ESMO Asia | Professor Liangyou Gu: Disitamab Vedotin Plus Immunotherapy Brings New Hope for Adjuvant Treatment of UTUC

    1. Challenges of Adjuvant Therapy in Locally Advanced UTUC Compared with bladder cancer, UTUC is more aggressive and associated with poorer outcomes. Even after radical surgery, the 5-year disease-free survival…

    2025.12.18
  • Professor Peng Zhang: The HOPE Program Paves the Way for Bladder-Preserving Care in Urothelial Carcinoma

    Oncology Frontier – UroStream: The West China urology team has accumulated extensive experience in urothelial carcinoma. In the exploration of ADC-based neoadjuvant/adjuvant therapy and organ-preserving strategies, what key clinical studies…

    2025.12.18
  • ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

    Title CD7 CAR-T Cell Therapy Based on “Natural Selection” for the Treatment of Relapsed or Refractory CD7-Positive Hematologic Malignancies: A Large Cohort Study Chinese Title 基于“自然选择”平台的CD7 CAR-T细胞治疗复发/难治性CD7阳性血液系统恶性肿瘤:一项大样本队列研究 First Author Zhang…

    2025.12.18
  • ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

    Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…

    2025.12.17
  • ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

    On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…

    2025.12.17
  • ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

    From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…

    2025.12.17
  • ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

    At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…

    2025.12.17
«previous next»
Recent Posts
  • Professor Zefei Jiang: The Northern Breast Cancer Salon Returns
  • 2026 CASH丨Professor Xiaofan Zhu: New Directions in Pediatric Hematologic Malignancies Through the Lens of ASH Frontiers
  • 2026 CASH | Professor Jianqing Mi: Advances and Future Directions of CAR-T Cell Therapy in Multiple Myeloma
  • 2026 CASH | Professor Lugui Qiu: Annual Review of the 2025 Multiple Myeloma Guidelines
  • CASH 2026 | Prof. Wang Tianyou: Forty Years of Change in China’s Pediatric Disease Spectrum and Strategic Responses
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top